Uncategorised

Uncategorised news under IP law

Nike-New Balance Patent Lawsuit Paused Amid PTAB Review, Judge Rules

by

A federal judge has paused a high-stakes patent dispute between global sportswear giants Nike Inc. and New Balance Athletics, Inc., granting a temporary stay in litigation as the U.S. Patent Trial and Appeal Board (PTAB) reviews several of Nike’s Flyknit patents at the heart of the case.

On June 6, U.S. District Judge Julia E. Kobick ruled in favor of New Balance’s motion to stay the case until August 9, 2025, aligning with the expected PTAB decisions. Nike alleges that New Balance infringed on nine of its Flyknit patents across 61 different shoe models, claiming that the Boston-based company copied its innovative, lightweight knit sneaker technology.

New Balance requested the pause, citing that the PTAB is already actively reviewing six of the nine contested patents. The company argued that a stay would promote judicial efficiency and possibly narrow or eliminate the need for trial if some patents are invalidated.

Judge Kobick, in her ruling, agreed with New Balance’s position, stating that continuing the case while the PTAB deliberates could lead to duplicative proceedings. “Nike has not shown that it will suffer undue prejudice beyond the delay,” Kobick noted, indicating that a short pause would not cause significant harm to the plaintiff.

The judge also highlighted New Balance’s commitment to continue discovery during the stay, including the collection of documents and depositions from international partners. This assurance helped alleviate concerns about lost evidence or unavailable witnesses during the delay.

Nike’s Flyknit technology, first introduced in 2012, is considered a major breakthrough in performance footwear design. The company holds several patents on the material structure, stitching techniques, and manufacturing methods used to create a sock-like fit with minimal waste. Nike contends that New Balance’s knit-based designs unlawfully mirror its patented Flyknit technology.

If the PTAB invalidates some or all of the Flyknit patents under review, it could significantly alter the direction of the case, weakening Nike’s claims and reducing the number of infringing products. Conversely, if the patents are upheld, New Balance may face greater legal exposure and could be required to stop sales or negotiate licensing terms.

The litigation pause is temporary, with proceedings expected to resume following the PTAB’s decisions in August. The outcome will be closely watched by the industry, as it may set a precedent for how similar intellectual property disputes are handled between major athletic brands.

For now, both companies await the PTAB’s judgment, which could either simplify the lawsuit—or set the stage for a prolonged legal battle over innovation in athletic footwear.

Acadia Pharmaceuticals Clinches Patent Victory for NUPLAZID Composition

by

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) secured a critical legal win on Tuesday after the U.S. Court of Appeals for the Federal Circuit upheld the validity of the company’s composition of matter patent for its flagship drug, NUPLAZID (pimavanserin). The decision preserves Acadia’s exclusive rights under the ’740 patent and delivers a setback to challengers MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc.

The court’s affirmation confirms a lower court ruling that had sided with Acadia in its patent dispute, cementing the biotech firm’s control over the proprietary formulation of NUPLAZID, a therapy approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

“This ruling reinforces the strength of our intellectual property portfolio and our commitment to defending the innovation behind NUPLAZID,” said Steve Davis, CEO of Acadia Pharmaceuticals, in a statement following the announcement. “We are pleased that the court has once again validated our patent, enabling us to continue focusing on delivering therapies to patients with unmet medical needs.”

The legal battle stemmed from efforts by MSN Laboratories and its U.S. affiliate to invalidate Acadia’s ’740 patent, which they argued was not novel or sufficiently inventive. The appellate court rejected these arguments, siding with the company and affirming the patent’s enforceability until its expiration.

The timing of the ruling coincides with Acadia’s robust financial performance. Over the last twelve months, the company has reported revenues nearing $1 billion, with a notable 60% gross margin—a figure that highlights operational efficiency and pricing power in the specialty pharmaceutical market. According to InvestingPro, Acadia currently boasts a “GREAT” financial health score, with more than ten positive metrics contributing to its investment outlook.

Legal experts suggest this ruling will deter potential generic competition in the near term, securing continued market exclusivity for Acadia and potentially preserving its revenue stream from NUPLAZID. The drug remains the first and only FDA-approved treatment for Parkinson’s disease psychosis, positioning it as a valuable asset in Acadia’s expanding neuroscience pipeline.

With the legal hurdle now cleared, analysts anticipate that Acadia will intensify its strategic investments in late-stage clinical programs and explore additional therapeutic indications for pimavanserin.

The decision not only strengthens Acadia’s intellectual property rights but also underscores the importance of robust patent protection in the competitive pharmaceutical sector, where market exclusivity often dictates the pace of innovation and return on investment.

About Acadia Pharmaceuticals:
Founded in 1993 and headquartered in San Diego, California, Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address central nervous system disorders. Its lead product, NUPLAZID, is approved in the U.S. and continues to be studied for multiple neuropsychiatric indications.

Shoolini University Celebrates Fourth Innovation Day, Champions ‘One Student, One Patent’ Vision

by

Shoolini University, a leading private research-focused institution in India, celebrated the fourth edition of its flagship event, Shoolini Innovation Day, on Tuesday. The annual event, spearheaded by the university’s Intellectual Property Rights Office (SIPRO), served as a vibrant platform to promote innovation, research, and intellectual property creation among students and faculty.

The central theme of this year’s celebration—“One Student, One Patent”—reaffirmed the university’s bold ambition to make intellectual property a defining element of academic excellence. With participation from across disciplines, the event emphasized Shoolini’s growing reputation as a hub of patent-driven research and startup incubation.

A Platform for Innovation and Recognition

The celebration brought together a wide array of stakeholders, including student innovators, faculty researchers, patent attorneys, and industry experts. A series of exhibitions, interactive sessions, and panel discussions highlighted pioneering research projects and patents filed by the university community.

In his opening remarks, Vice-Chancellor Prof. Atul Khosla lauded the students and faculty for their contributions to India’s knowledge economy. “Innovation is not just a buzzword at Shoolini; it is part of our DNA. The ‘One Student, One Patent’ initiative aims to empower every learner to think beyond textbooks and contribute to real-world solutions,” he said.

SIPRO: Driving the IP Ecosystem

The Shoolini Intellectual Property Rights Office (SIPRO) has played a central role in facilitating the university’s rapid rise in patent filings. Through workshops, mentorship, and legal support, SIPRO has enabled students and researchers to navigate the complex terrain of intellectual property rights with confidence.

Over the past year, SIPRO has supported the filing of over 300 patents, spanning diverse areas such as biotechnology, pharmaceuticals, agriculture, environmental engineering, and artificial intelligence. Many of these patents have resulted from undergraduate and postgraduate research, reflecting a democratization of innovation on campus.

Students at the Forefront

A highlight of the event was the felicitation of student inventors whose work has already received patent grants or is in advanced stages of the application process. The stories of these students—ranging from low-cost water purification systems to AI-based medical diagnostics—offered a glimpse into the practical and socially relevant impact of their innovations.

Speaking at the event, Dr. Anuradha Sharma, Director of SIPRO, emphasized the importance of cultivating early IP literacy. “We are building a future where students see themselves as creators and protectors of knowledge. Our goal is to make patent filing as common as submitting a project report,” she stated.

Collaboration and Future Vision

The event also featured a roundtable discussion on the future of innovation in Indian universities, with participation from industry partners, government representatives, and IP professionals. Collaborations with startups, incubators, and technology transfer agencies were discussed as key enablers to take Shoolini’s patented innovations to market.

Concluding the event, Chancellor Prof. P.K. Khosla reiterated the university’s long-term commitment to IP-driven growth. “Innovation is the currency of the future. Our students must not only dream big but also protect and commercialize their ideas. This is how we will contribute to national development and global progress,” he remarked.

Building a Patent-First Academic Culture

As Shoolini University continues to climb national and global innovation rankings, Shoolini Innovation Day stands as a testament to its strategic investment in intellectual property. With the continued momentum of initiatives like “One Student, One Patent,” the university is poised to emerge as a model for academic institutions aspiring to lead in innovation, research, and IP commercialization.

Piyush Goyal Rejects Allegations of IPR Violations, Calls Them ‘Myths’ Without Basis

by

India’s Union Minister for Commerce and Industry, Piyush Goyal, firmly refuted recent claims of intellectual property rights (IPR) violations during a press interaction in Bern. Speaking to international media while attending high-level trade discussions in Switzerland, Goyal dismissed allegations of trademark, patent, and copyright infringement as “myths” lacking any concrete evidence.

“Show me one instance where we have illegally copied any trademarks, patents, or copyrighted technology. Not one has been presented,” Goyal said, responding to concerns raised by foreign industry lobbies and some international commentators. He emphasized that India is committed to a transparent and rules-based intellectual property ecosystem, and accused certain vested interests of perpetuating outdated stereotypes.

Defending India’s Innovation Landscape

Goyal highlighted that India has made significant strides in strengthening its IPR regime in line with global standards. “India respects innovation and creativity. Our patent laws, copyright enforcement, and trademark regulations are fully TRIPS-compliant,” he asserted, referring to the World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights.

The Minister also pointed to India’s growing contributions to global innovation, particularly in sectors such as pharmaceuticals, information technology, and green energy. He underscored India’s role in providing affordable healthcare and technology solutions to the developing world without compromising intellectual property norms.

Countering Protectionist Narratives

Goyal’s remarks come at a time when some developed nations have expressed concerns about alleged misuse of patented technologies and trademarked products by Indian manufacturers. Industry associations from Europe and North America have, in the past, accused Indian firms of reverse-engineering Western products.

In response, Goyal stated that such criticisms often ignore the spirit of open innovation and are rooted in protectionist agendas. “We will not allow unfounded allegations to undermine India’s reputation. We follow due process, encourage licensing arrangements, and promote indigenous R&D,” he added.

Emphasis on Fair Global Trade

The Minister reiterated India’s commitment to fair global trade practices and called on international partners to engage constructively. He also mentioned India’s recent initiatives to streamline patent processing, strengthen copyright adjudication, and enhance awareness among startups and MSMEs regarding intellectual property.

India’s efforts to foster a culture of innovation have been recognized by global indices. The country ranked 40th in the Global Innovation Index 2023, its highest-ever position, marking a steady climb in recent years.

Looking Ahead

As India continues to integrate into global value chains and negotiates trade agreements with partners such as the European Free Trade Association (EFTA), Goyal’s strong defense of India’s IPR framework sends a clear message. It underscores New Delhi’s resolve to challenge what it sees as unfair narratives while promoting a robust and equitable innovation environment.

“Let’s move past assumptions and work towards genuine partnerships,” Goyal concluded, calling on stakeholders to recognize India not just as a manufacturing hub, but as a responsible player in global intellectual property governance.

Kerala University Secures Patent for Eco-Friendly Solar Cell Technology

by

In a significant stride toward sustainable energy solutions, the University of Kerala has secured a patent for an innovative eco-friendly solar cell technology. This pioneering development stems from a collaborative effort between the University’s Departments of Physics and Botany, working under the aegis of its Translational Research and Innovation Centre (TRIC-KU).

The patented technology represents a new generation of photovoltaic cells that utilize biodegradable, plant-based materials in place of conventional, environmentally hazardous components. According to university officials, this approach not only reduces the ecological footprint of solar panel production but also enhances affordability and efficiency, especially in tropical regions like Kerala.

A Synergistic Research Model

The breakthrough underscores the success of interdisciplinary collaboration. While the Department of Physics focused on the structural and energy conversion aspects of the solar cells, the Department of Botany contributed crucial insights into the biological materials used to replace synthetic polymers and toxic metals typically found in conventional photovoltaic systems.

“This is a proud moment for Kerala University and a testament to what can be achieved when scientific disciplines converge with a shared purpose,” said Dr. R. S. Suresh, Director of TRIC-KU. “Our aim was to create a clean energy solution that aligns with both ecological and economic sustainability, and this patent is a validation of our vision.”

Technology Rooted in Nature

The solar cells developed by the research team incorporate organic dyes extracted from native plant species as photosensitizers, replacing the more commonly used but environmentally detrimental synthetic chemicals. These natural dyes absorb sunlight and initiate the photoelectric conversion process, mimicking the way plants conduct photosynthesis.

Additionally, the researchers have replaced rare and expensive materials like platinum and ruthenium with easily available carbon-based and bio-derived alternatives, further reducing the cost and environmental impact of production.

Towards Commercialization

With the patent now secured, Kerala University is actively exploring partnerships with clean tech companies and government agencies to commercialize the product. Pilot installations are already being planned across select university campuses and rural community centers in the state, in a bid to test scalability and real-world performance.

Dr. Asha Menon, lead researcher from the Department of Botany, emphasized the broader potential of the technology. “This innovation goes beyond academic achievement. It’s a tangible step toward democratizing access to renewable energy, particularly in resource-constrained settings where cost and environmental considerations are paramount.”

Institutional Push for Innovation

This development is the latest in a series of achievements under the University’s Translational Research and Innovation Centre, which was established to bridge the gap between laboratory research and real-world applications. TRIC-KU aims to transform fundamental research into market-ready technologies, with a special focus on sustainability, health, and energy.

Vice Chancellor Dr. Mohan Kumar congratulated the research team and reaffirmed the university’s commitment to fostering innovation. “Securing this patent places Kerala University on the global map of green technology research. It also aligns with India’s broader mission to transition towards cleaner, more sustainable energy systems.”

Looking Ahead

As climate change accelerates and the world turns increasingly toward renewable energy, Kerala University’s eco-friendly solar cell technology offers a beacon of innovation rooted in local knowledge and global relevance. The institution hopes this patent will pave the way for further research into nature-based solutions that blend science, sustainability, and social impact.

Russia Patents Groundbreaking Technology to Launch Automatic Spacecraft from Orbital Station

by

In a bold step toward space autonomy and robotic exploration, Russia has secured a patent for a revolutionary technology that will enable the automatic launch of spacecraft from an orbital station, marking a significant advancement in the country’s space capabilities. The innovation also aims to establish the world’s first drone platform in space, maintained by robotic systems, laying the groundwork for sustained lunar exploration and deep-space missions.

The announcement was made following a high-level briefing by First Deputy Prime Minister Denis Manturov to President Vladimir Putin, where Manturov underscored the strategic importance of the new technology for Russia’s long-term space goals. He confirmed that the Russian Orbital Station (ROS) will serve as the testing ground for this cutting-edge system, which forms a core component of the nation’s roadmap to build and operate its own orbital infrastructure independent of the International Space Station (ISS).

A New Era in Space Autonomy

The patented technology envisions a fully automated launch platform in orbit, capable of deploying unmanned spacecraft with minimal human intervention. This system will integrate a fleet of space drones supported by onboard robotic maintenance units, enabling frequent missions for satellite deployment, cargo transport, orbital repairs, and planetary reconnaissance.

According to official sources, this innovation could dramatically reduce the logistical burdens and costs associated with launching spacecraft from Earth-based platforms. By establishing a modular launch capability in orbit, Russia aims to boost mission flexibility, especially for low-gravity operations near the Moon and in cis-lunar space.

“The use of robotic systems for servicing a space-based drone platform is a breakthrough for orbital logistics and planetary exploration,” said a senior Roscosmos engineer involved in the project. “We are talking about a platform that can maintain itself and autonomously prepare vehicles for launch — a key to future interplanetary missions.”

Strategic Transition to the Russian Orbital Station (ROS)

Deputy Prime Minister Manturov reaffirmed the government’s commitment to achieving a planned module-by-module transition to the Russian Orbital Station by 2030. The ROS project, a flagship venture of Russia’s post-ISS strategy, is being developed to ensure sovereign space operations, scientific research, and commercial missions without reliance on international partnerships.

The ROS will serve as both a testing and operational base for the newly patented drone launch technology. It is designed to support a variety of payloads, robotic systems, and automated modules that can dock, refuel, and redeploy without human crew present.

President Putin, during the meeting, emphasized the need to fast-track technological self-sufficiency in space, particularly in light of growing geopolitical tensions and evolving global competition in lunar exploration. The initiative is also seen as a direct response to U.S. and Chinese plans to establish lunar bases and orbital platforms of their own.

Implications for Lunar Missions

Officials from Roscosmos have confirmed that the automatic launch platform will play a central role in Russia’s lunar exploration strategy, including future robotic landers, orbiters, and sample-return missions. The modularity and autonomy of the system make it ideal for assembling and dispatching spacecraft aimed at the Moon’s surface and potentially beyond.

Industry analysts suggest that this development could enable Russia to conduct more frequent, lower-cost lunar missions, including support for the long-anticipated Luna-27 and Luna-28 programs, and even collaborative efforts under BRICS or Eurasian space initiatives.

Global Significance

If successfully implemented, Russia’s orbital drone platform could represent the first of its kind in space history, introducing a new paradigm where maintenance, assembly, and launch of spacecraft are entirely managed by machines in orbit.

“This is not just about a patent—it’s about redefining space logistics,” said Dr. Elena Kurbatova, a space policy analyst at the Moscow Institute of Aviation and Space Law. “The implications for space commercialization, planetary defense, and autonomous exploration are immense.”

Looking Ahead

While technical challenges remain — particularly in AI coordination, robotic reliability, and orbital resource management — Russia’s commitment to transitioning to the ROS by 2030 indicates a determined effort to reshape its role in the global space race. The country’s growing portfolio of space patents and its investment in autonomous systems signal an era of strategic innovation driven by long-term exploration goals.

As the ROS begins to take shape and tests commence in the coming years, all eyes will be on Russia to see whether it can turn this ambitious vision of robotic spaceflight and in-orbit autonomy into a reality.

DrivebuddyAI Awarded Patent for Advanced Driver Drowsiness Detection Technology

by

Indian deep-tech startup DrivebuddyAI has been granted a patent for its driver drowsiness detection system, a major milestone in the company’s mission to enhance road safety through artificial intelligence and computer vision. The patented innovation uses advanced machine learning algorithms to detect signs of fatigue in drivers, aiming to reduce road accidents caused by human error.

The patent, titled “System and Method for Real-time Detection of Driver Drowsiness Using AI”, was awarded by the Indian Patent Office in recognition of DrivebuddyAI’s novel approach that combines real-time video analytics with physiological behavior modeling. The technology analyzes visual cues such as eyelid closure rate, head movement, yawning frequency, and eye-gaze patterns to detect signs of fatigue or microsleep in drivers.

Bridging the Gap in Road Safety

Founded in 2018, DrivebuddyAI has been working at the intersection of automotive safety and AI. The startup’s technology is already being used in commercial fleets, transport companies, and driver training centers across India and Southeast Asia. With the grant of this patent, DrivebuddyAI now holds exclusive rights to commercialize its drowsiness detection system in India, giving it a competitive edge in the rapidly growing AI-powered mobility sector.

“Getting the patent is a strong validation of our innovation and the years of research that went into building this technology,” said Prateek Chauhan, CEO and Co-founder of DrivebuddyAI. “Driver fatigue is one of the leading causes of road fatalities worldwide. Our solution helps address this problem in real-time by alerting the driver and the fleet operator before a mishap occurs.”

How the Technology Works

Unlike traditional systems that rely on wearable sensors or steering input, DrivebuddyAI’s approach is entirely non-intrusive. A camera installed inside the vehicle’s cabin monitors the driver’s facial features and behavioral indicators. Using deep neural networks trained on thousands of hours of driving data, the system generates fatigue alerts when certain thresholds are crossed.

The system is also integrated with DrivebuddyAI’s broader telematics platform, enabling fleet managers to view drowsiness reports, analyze risk profiles, and implement proactive safety measures.

Alignment with Government Goals

The patent award comes at a time when both the Ministry of Road Transport and Highways and NITI Aayog have emphasized the need for technology-based interventions to reduce India’s high rate of road accidents. According to government statistics, driver fatigue contributes to nearly 20% of highway accidents.

Industry experts see DrivebuddyAI’s patented solution as a timely innovation that aligns with India’s push for intelligent transport systems (ITS) and safer roads under initiatives like Bharat NCAP and the National Road Safety Policy.

Future Plans

With the patent secured, DrivebuddyAI plans to further refine the technology and expand its application to ADAS (Advanced Driver Assistance Systems) and autonomous driving modules. The startup also aims to enter global markets, particularly in the Middle East, Europe, and Southeast Asia, where demand for fleet safety solutions is rapidly increasing.

The company is currently in talks with OEMs and tier-1 suppliers to embed its AI modules in upcoming commercial and passenger vehicles.

About DrivebuddyAI

DrivebuddyAI specializes in AI-powered driver monitoring systems (DMS), video telematics, and behavior analytics aimed at making roads safer and fleets smarter. The company has raised funding from angel investors and is supported by industry partners including NVIDIA and the Automotive Research Association of India (ARAI).

How India’s Evolving Patent Law Transformed Its Pharma Industry from Generics to Innovation Powerhouse

by

India’s pharmaceutical landscape has undergone a seismic transformation over the past two decades, evolving from a generics powerhouse to a burgeoning hub for global research and development (R&D). Central to this shift has been the country’s evolving patent regime—particularly the changes ushered in by the Patents (Amendment) Act, 2005—which reshaped industry strategies, attracted global collaborations, and propelled Indian companies onto the global innovation map.

A Generics Legacy Rooted in Policy

Until the early 2000s, India’s pharmaceutical industry thrived on the back of a legal framework that permitted the manufacture of generic versions of patented drugs through a process patent regime. Introduced by the Indian Patents Act of 1970, this approach enabled Indian firms to reverse-engineer drugs and develop cost-effective alternatives, making life-saving medicines affordable domestically and in developing countries worldwide.

By the late 1990s, Indian pharmaceutical companies like Cipla, Dr. Reddy’s Laboratories, and Ranbaxy had become synonymous with generic drug manufacturing, supplying affordable antiretrovirals during the global HIV/AIDS crisis.

WTO Obligations and the 2005 Patent Shift

India’s accession to the World Trade Organization (WTO) in 1995 came with commitments under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement. A critical requirement was to transition to a product patent regime, granting stronger intellectual property protection for pharmaceuticals.

The watershed moment came with the Patents (Amendment) Act, 2005. The Act introduced product patents for pharmaceuticals, thereby aligning India’s patent laws with TRIPS. The legislation marked a paradigm shift—no longer could Indian firms freely replicate patented drugs without licensing.

However, the amendment also included critical public interest safeguards. Section 3(d) of the Act, for instance, disallowed patents on “incremental innovations” unless they showed enhanced efficacy. This clause became pivotal in landmark cases such as Novartis v. Union of India, where India’s Supreme Court denied patent protection to the cancer drug Glivec in 2013.

The R&D Pivot

With limitations on reverse engineering, Indian pharma companies began investing more heavily in original drug discovery and innovation. The post-2005 environment incentivized a shift from pure generics manufacturing to novel drug development, biosimilars, and proprietary research.

Companies like Sun Pharma, Biocon, and Glenmark Pharmaceuticals ramped up their R&D budgets and established global partnerships to tap into advanced therapeutic areas such as oncology, biologics, and immunotherapy. India’s Contract Research Organizations (CROs) also gained prominence, supporting global pharma firms with clinical trials and drug development services.

The government reinforced this innovation-centric approach by launching schemes like the Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS) and strengthening IP awareness through initiatives under the National IPR Policy (2016).

Global Collaborations and Patent Filings Surge

India’s R&D-driven strategy yielded tangible results. According to the Indian Patent Office, pharma-related patent applications by Indian entities have grown steadily, with a 2.3x increase between 2015 and 2023. Multinational companies, recognizing India’s scientific talent and cost efficiencies, expanded R&D collaborations and opened innovation centers in cities like Hyderabad, Bengaluru, and Ahmedabad.

Moreover, Indian pharmaceutical innovators have gained recognition in advanced markets. Biocon’s approval for biosimilars in the US and EU, and Zydus Cadila’s development of India’s first DNA-based COVID-19 vaccine, ZyCoV-D, stand as testament to the country’s growing scientific capabilities.

Balancing Innovation and Access

Despite this transition, India continues to balance innovation with public health needs. Compulsory licensing provisions and the continued application of Section 3(d) ensure that patent rights do not come at the cost of affordable healthcare. Critics from the global pharmaceutical lobby often view these safeguards as hurdles to innovation, but public health advocates argue they are necessary for equitable access.

The Road Ahead

India’s pharmaceutical evolution is far from complete. With 6G connectivity, AI-driven drug discovery, and personalized medicine on the horizon, the next frontier for Indian pharma will likely involve deep tech and cross-disciplinary innovation. Government initiatives like the Bulk Drug Parks and the PLI (Production-Linked Incentive) Scheme for pharmaceuticals are expected to accelerate this transformation.

India’s patent law has not merely redefined legal boundaries; it has charted a new course for the pharmaceutical industry—one where affordable medicine and cutting-edge innovation can, and must, coexist.

Garmin Files Patent for Smartwatch with Non-Invasive Blood Sugar Monitoring Technology

by

Garmin, a leading name in GPS and wearable technology, has filed a new patent that could significantly advance the future of digital health. The patent outlines a non-invasive blood glucose monitoring system integrated into its smartwatches, aiming to offer users a pain-free, continuous glucose tracking solution without the need for traditional finger-prick tests.

The innovation centers around light-based sensors, commonly referred to as photoplethysmography (PPG) or spectroscopy techniques, to analyze glucose levels through the skin. According to the patent documents, the smartwatch would emit specific wavelengths of light to penetrate the skin and detect variations in blood composition, including glucose concentration.

A Game-Changer in Glucose Monitoring

This development could be especially impactful for people managing diabetes or prediabetes, offering a convenient, non-invasive method for tracking blood sugar levels throughout the day. Unlike current continuous glucose monitors (CGMs) that typically require a sensor to be inserted under the skin, Garmin’s solution could eliminate the need for consumables or invasive procedures.

The system is expected to provide long-term trends and insights, allowing users to better understand how their lifestyle, diet, and activity levels affect their glucose metabolism. This aligns with Garmin’s broader strategy of expanding its health and wellness capabilities, reinforcing its position in a growing market that increasingly demands wearable-based health diagnostics.

Potential Capabilities Highlighted in the Patent

The patent describes the integration of a multi-sensor array capable of filtering out noise from other biological signals, such as heart rate or hydration levels, thereby improving the accuracy of glucose detection. The device could also work in tandem with Garmin’s suite of fitness metrics—like heart rate variability, sleep patterns, and stress monitoring—to deliver a comprehensive health profile.

While no official release timeline has been shared, Garmin’s entry into the blood glucose monitoring space reflects the broader trend of convergence between consumer electronics and medical diagnostics. Apple, Samsung, and several health tech startups have also been exploring similar non-invasive technologies, but commercial viability and clinical accuracy remain key challenges.

Regulatory and Market Implications

If Garmin’s device meets regulatory standards for accuracy and reliability, it could disrupt the global glucose monitoring market, currently valued at over $15 billion. Non-invasive solutions are considered the “holy grail” of diabetes care due to the convenience and user compliance they offer.

Experts suggest that Garmin may initially roll out the technology as a wellness feature before seeking FDA or CE approval for medical-grade use, a common approach in wearable health innovations.

Looking Ahead

Garmin’s patent marks a significant step forward in the evolution of smartwatches from fitness accessories to comprehensive health monitoring tools. As the race to develop non-invasive glucose tracking heats up, the company’s engineering strength and credibility in sensor technology may give it a competitive edge.

While the technology is still in the developmental stage, its potential to improve quality of life and promote preventive healthcare is immense, signaling a promising shift in the wearable tech landscape.

Hyderabad Cardiologist’s Groundbreaking Cardiac Device Wins US Patent

by
In a significant advancement for cardiac healthcare, an innovative medical device developed by Hyderabad-based pediatric cardiologist Dr. Nageswara Rao Koneti has been granted a United States patent. The invention, named the **KONAR-MF Occluder**, is designed to treat a wide range of congenital and acquired heart defects, making it a potential game-changer in cardiology worldwide.

Dr. Koneti, who leads the Cardiology Division at Rainbow Children’s Heart Institute in Hyderabad, spent over six years developing the KONAR-MF (Multi-Functional) Occluder. The device is engineered to close septal defects—abnormal openings in the heart—found in both children and adults.

At the heart of this innovation lies a **double umbrella disc structure** crafted from **nitinol**, a nickel-titanium alloy known for its flexibility and biocompatibility. The device is designed to be stretchable up to 15 mm, enabling it to adapt to varying defect sizes and shapes during minimally invasive procedures.

“This device can treat multiple complex cardiac conditions, including ventricular septal defects (VSDs), coronary arteriovenous fistulas, and paravalvular leaks,” said Dr. Koneti.

The KONAR-MF Occluder has already been recognized internationally. It holds patents in India, Europe (under the European Commission), several Euro-African countries, and South Korea. The addition of a U.S. patent not only underscores the global relevance of the device but also opens the door for broader clinical application and commercialization in North America.

Cardiologists often face challenges when dealing with complex septal defects due to the varying anatomical presentations and the need for precision closure to avoid complications. The KONAR-MF Occluder’s flexible and adaptive design seeks to address these clinical challenges by offering a reliable, minimally invasive solution.

“This is not just a win for me personally but a step forward for Indian medical innovation,” Dr. Koneti stated. “Our goal was to create a single device that could serve multiple purposes in cardiology, especially in regions where access to advanced medical infrastructure is limited.”

The device has already shown promising results in clinical trials, and further studies are being planned to evaluate long-term outcomes and expand its indications. With the U.S. patent secured, Dr. Koneti and his team hope to collaborate with global manufacturers and healthcare providers to bring this device into widespread use.

As congenital heart disease remains one of the most common birth defects globally, innovations like the KONAR-MF Occluder offer hope for safer, more effective treatments—especially in resource-limited settings. The global cardiology community will be watching closely as this device begins its journey into mainstream cardiac care.